NASDAQ: HRMYHarmony Biosciences Holdings Inc Stock
$35.20-0.28 (-0.79%)
Updated Jun 11, 2026
HRMY Price
$35.20
Fair Value Price
N/A
Market Cap
$2.04B
52 Week Low
$25.52
52 Week High
$40.87
P/E
13.91x
P/B
2.24x
P/S
1.8x
PEG
0.53x
Dividend Yield
N/A
Revenue
$899.11M
Earnings
$145.62M
Gross Margin
76.5%
Operating Margin
23.54%
Profit Margin
16.2%
Debt to Equity
0.4
Operating Cash Flow
$342M
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HRMY Overview
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HRMY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HRMY
Ranked#68 of 463
Ranked#68 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important HRMY news, forecast changes, insider trades & much more!
HRMY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HRMY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HRMY ($35.20) is trading below its intrinsic value of $35.61, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HRMY is good value based on its earnings relative to its share price (13.91x), compared to the US market average (13.95x)
P/E vs Market Valuation
HRMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more HRMY due diligence checks available for Premium users.
Valuation
HRMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
13.91x
Industry
17.66x
Market
13.95x
HRMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HRMY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
HRMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.24x
Industry
4.83x
HRMY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HRMY price to earnings growth (PEG)
For valuing profitable companies with growth potential
HRMY is good value based... subscribe to Premium to read more.
PEG Value Valuation
HRMY's financial health
Profit margin
Revenue
$215.4M
Net Income
$32.5M
Profit Margin
15.1%
HRMY's Earnings (EBIT) of $211.62M... subscribe to Premium to read more.
Interest Coverage Financials
HRMY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$361.5M
Debt to equity
0.4
HRMY's short-term assets ($778.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HRMY's short-term assets ($778.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HRMY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HRMY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$27.8M
Investing
-$183.6M
Financing
-$7.2M
HRMY's operating cash flow ($341.97M)... subscribe to Premium to read more.
Debt Coverage Financials
HRMY vs Biotech Stocks
Harmony Biosciences Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.